gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Phosphodiesterase 4B, cAMP-specific

PDE4B, phosphodiesterase 4B
This gene is a member of the type IV, cyclic AMP (cAMP)-specific, cyclic nucleotide phosphodiesterase (PDE) family. Cyclic nucleotides are important second messengers that regulate and mediate a number of cellular responses to extracellular signals, such as hormones, light, and neurotransmitters. The cyclic nucleotide phosphodiesterases (PDEs) regulate the cellular concentrations of cyclic nucleotides and thereby play a role in signal transduction. This gene encodes a protein that specifically hydrolyzes cAMP. Altered activity of this protein has been associated with schizophrenia and bipolar affective disorder. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Phosphodiesterase, PDE4D, PDE, HAD, DISC1
Papers on PDE4B
Cyclic nucleotide phosphodiesterase isoforms in human basophils and mast cells.
Peachell et al., Eşfahān, Iran. In Int J Immunopathol Pharmacol, Feb 2016
In basophils, prominent expression of mRNA for PDE4A and PDE4D was observed whereas little if any expression of PDE4B and PDE4C was detected.
The Prediction of the Expected Current Selection Coefficient of Single Nucleotide Polymorphism Associated with Holstein Milk Yield, Fat and Protein Contents.
Kim et al., Seoul, South Korea. In Asian-australas J Anim Sci, Jan 2016
They are phosphodiesterase 4B (PDE4B), serine/threonine kinase 40 (STK40), collagen, type XI, alpha 1 (COL11A1), ephrin-A1 (EFNA1), netrin 4 (NTN4), neuron specific gene family member 1 (NSG1), estrogen receptor 1 (ESR1), neurexin 3 (NRXN3), spectrin, beta, non-erythrocytic 1 (SPTBN1), ADP-ribosylation factor interacting protein 1 (ARFIP1), mutL homolog 1 (MLH1), transmembrane channel-like 7 (TMC7), carboxypeptidase X, member 2 (CPXM2) and ADAM metallopeptidase domain 12 (ADAM12).
Intrathecal injection of phosphodiesterase 4B-specific siRNA attenuates neuropathic pain in rats with L5 spinal nerve ligation.
Zhang et al., Nanjing, China. In Mol Med Report, Jan 2016
These results suggested that selective inhibition of PDE4B may relieve neuropathic pain, potentially via the suppression of glial activation and the release of cytokines in the spinal cord.
Design and Synthesis of Substituted Pyridazinone-1-Acetylhydrazones as Novel Phosphodiesterase 4 Inhibitors.
Piazza et al., Asyūţ, Egypt. In Arch Pharm (weinheim), Jan 2016
UNASSIGNED: A series of novel pyridazin-6-one-1-acetylhydrazone hybrids were rationally designed to inhibit phosphodiesterase 4 (PDE4B).
Association of PDE4B Polymorphisms with Susceptibility to Schizophrenia: A Meta-Analysis of Case-Control Studies.
Shi et al., Xinxiang, China. In Plos One, Dec 2015
BACKGROUND: The PDE4B single nucleotide polymorphisms (SNPs) have been reported to be associated with schizophrenia risk.
Studying mechanisms of cAMP and cyclic nucleotide phosphodiesterase signaling in Leydig cell function with phosphoproteomics.
Ong et al., Washington, D.C., United States. In Cell Signal, Dec 2015
We have recently shown that PDE4B and PDE4C as well as PDE8A and PDE8B are expressed in rodent Leydig cells and that combined inhibition of PDE4 and PDE8 leads to dramatically increased steroid biosynthesis.
Synthesis of new congeners of 1-methyl-3-aminoisoquinolines, evaluation of their cytotoxic activity, in silico and in vitro study of their molecular targets as PDE4B.
Chigorina et al., Moscow, Russia. In Chem Biol Drug Des, Dec 2015
By contrast, 50μM of 4c and 4d inhibited the growth of HKe3-mtKRAS spheroids in the 3D floating (3DF) culture suggesting that 4c and 4d targets PDE4B which is selectively upregulated by mtKRAS in 3DF culture.
Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.
Burgin et al., Grand Rapids, United States. In Neurotherapeutics, 2015
PDE4B-NAMs have the potential to reduce neuroinflammation by dampening microglia cytokine production triggered by brain amyloid, while PDE4D-NAMs have potent cognitive benefit by augmenting signaling through the cAMP/protein kinase A/cAMP response element-binding protein (CREB) pathway for memory consolidation.
Reliability of Virtual Screening Methods in Prediction of PDE4B-inhibitor Activity.
Pentikainen et al., Jyväskylä, Finland. In Curr Drug Discov Technol, 2014
The aim of this study was to compare some commonly used computational methods to estimate their ability to separate highly active PDE4B-inhibitors from less active and inactive ones.
Selective Phosphodiesterase 4B Inhibitors: A Review.
Tripuraneni et al., Udagamandalām, India. In Sci Pharm, 2014
Phosphodiesterase 4B (PDE4B) is a member of the phosphodiesterase family of proteins that plays a critical role in regulating intracellular levels of cyclic adenosine monophosphate (cAMP) by controlling its rate of degradation.
Association of PDE4B polymorphisms and schizophrenia in Northwestern Han Chinese.
Li et al., Xi'an, China. In Hum Genet, 2012
a study of Northwestern Han Chinese found that rs472952 is significantly associated with schizophrenia (SCZ) and rs7537440 is associated with SCZ in females; results provide further evidence that PDE4B may play important roles in the etiology of SCZ
Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by Streptococcus pneumoniae by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway.
Li et al., Atlanta, United States. In J Biol Chem, 2012
PDE4B mediates ERK-dependent up-regulation of mucin MUC5AC by S. pneumoniae by inhibiting cAMP-PKA-dependent MKP-1 pathway.
Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer.
Naito et al., Fukuoka, Japan. In Prostate, 2012
PDE4B was downregulated and the protein kinase A pathway was activated in castration-resistant LNCaP prostate cancer cells. PDE4B expression was reduced in advanced prostate cancer and PDE4B knockdown promoted castration-resistant growth of LNCaP cells.
Phosphodiesterase 4 and its inhibitors in inflammatory diseases.
Lin et al., Taiwan. In Chang Gung Med J, 2012
Type 4 cyclic nucleotide phosphodiesterases (PDE4) are a family of low km 3',5'-cyclic adenosine monophosphate (cAMP)-specific phosphodiesterases including at least 20 isozymes encoded by four genes (PDE4A, PDE4B, PDE4C, and PDE4D) in mammals.
ZNF804a regulates expression of the schizophrenia-associated genes PRSS16, COMT, PDE4B, and DRD2.
Maher et al., United States. In Plos One, 2011
ZNF804a regulates expression of the schizophrenia-associated genes PRSS16, COMT, PDE4B, and DRD2
Regulation of murine cardiac function by phosphodiesterases type 3 and 4.
Backx et al., Toronto, Canada. In Curr Opin Pharmacol, 2011
Studies using transgenic models in combination with family-specific PDE inhibitors have demonstrated that PDE3A, PDE4B, and PDE4D isoforms regulate cardiac contractility by modulating cAMP levels in various subcellular compartments.
Bresol inhibits phosphodiesterase 4 gene expression and modulates the levels of select mediators of inflammation in human monocytic cells.
Patki et al., Bengaluru, India. In J Immunotoxicol, 2011
The reported anti-inflammatory activity of bresol might be attributed to its abilities to inhibit PDE4B and thus elevate cAMP levels in human monocytes.
DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling.
Porteous et al., Edinburgh, United Kingdom. In Science, 2005
a mechanistic model whereby DISC1 sequesters phosphodiesterase 4B in resting cells and releases it in an activated state in response to elevated cAMP
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
Zhang et al., Berkeley, United States. In Nat Biotechnol, 2005
A 4,000-fold increase in the potency of this PDE4 inhibitor was achieved after only two rounds of chemical synthesis and the structural analysis of seven pyrazole derivatives bound to PDE4B or PDE4D, revealing the robustness of this approach for identifying new inhibitors that can be further developed into drug candidates.
Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Lipworth, Dundee, United Kingdom. In Lancet, 2005
The therapeutic ratio for PDE4 inhibitors is thought to be determined by selectivity on receptor subtypes for relative effects on PDE4B (anti-inflammatory) and PDE4D (emesis).
share on facebooktweetadd +1mail to friends